Enlaza Therapeutics
LA JOLLA, CA · Biotechnology, Healthcare, Health Care · 55 employees
Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-Lock™ platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.
Funding history
- Funding Round — $15.0M — Sep 2025
- Funding Round — $84.0M — Aug 2024
- Funding Round — $35.3M — Nov 2022
- Funding Round — Undisclosed — Aug 2021
- Funding Round — Undisclosed — Jun 2021
Recent signals
- Sep 11, 2025: Raised $15.0M
- Aug 09, 2024: Raised $84.0M
- Nov 22, 2022: Raised $35.3M
- Aug 13, 2021: Raised Undisclosed
- Jun 28, 2021: Raised Undisclosed
- Mar 25, 2021: Raised $35.3M
See plans & pricing → Track Enlaza Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.